Skip to main content
Top
Published in: Journal of Cancer Survivorship 6/2020

01-12-2020 | Ovarian Cancer

Gynaecological cancer leads to long-term sick leave and permanently reduced working ability years after diagnosis

Authors: Trine Allerslev Horsbøl, Susanne Oksbjerg Dalton, Gunn Ammitzbøll, Christoffer Johansen, Elisabeth Anne Wreford Andersen, Pernille Tine Jensen, Ligita Paskeviciute Frøding, Henrik Lajer, Susanne K. Kjaer

Published in: Journal of Cancer Survivorship | Issue 6/2020

Login to get access

Abstract

Purpose

The aim of the study was to investigate overall patterns in labour market affiliation, risk for permanently reduced work ability and prevalence of long-term sickness absence among women diagnosed with gynaecological cancer.

Methods

We followed 8451 women diagnosed with ovarian, endometrial or cervical cancer, and 72,311 women with no history of cancer in nationwide registers for up to 19 years (mean 7.5 years). We computed hazards ratios for permanently reduced working ability and annual proportions of long-term sick leave.

Results

Patterns of labour market affiliation varied by cancer diagnosis and stage. The hazard of permanently reduced working ability was increased for survivors of all three cancers but most pronounced for women diagnosed with advanced ovarian cancer. The highest hazard ratios were found 2–5 years after diagnosis, and they persisted for years in all groups and throughout the follow-up period of 19 years in women diagnosed with advanced cervical cancer. In the subgroups of women who continued to be potentially active on the labour market, long-term sick leave was more prevalent among cancer survivors than women with no history of cancer up to 10 years after diagnosis.

Conclusions

Women diagnosed with localised as well as advanced gynaecological cancer are at prolonged risk for permanently reduced working ability and long-term sick leave.

Implications for Cancer Survivors

Gynaecological cancer can have long-term as well as permanent consequences for working ability, and survivors who remain active on the labour market might have to take more sick leave even years after cancer diagnosis than other women at their age.
Appendix
Available only for authorised users
Literature
27.
28.
go back to reference Stapelfeldt CM, Jensen C, Andersen NT, Fleten N, Nielsen CV. Validation of sick leave measures: self-reported sick leave and sickness benefit data from a Danish national register compared to multiple workplace-registered sick leave spells in a Danish municipality. BMC Public Health. 2012;12:661-2458-12-661. https://doi.org/10.1186/1471-2458-12-661.CrossRef Stapelfeldt CM, Jensen C, Andersen NT, Fleten N, Nielsen CV. Validation of sick leave measures: self-reported sick leave and sickness benefit data from a Danish national register compared to multiple workplace-registered sick leave spells in a Danish municipality. BMC Public Health. 2012;12:661-2458-12-661. https://​doi.​org/​10.​1186/​1471-2458-12-661.CrossRef
Metadata
Title
Gynaecological cancer leads to long-term sick leave and permanently reduced working ability years after diagnosis
Authors
Trine Allerslev Horsbøl
Susanne Oksbjerg Dalton
Gunn Ammitzbøll
Christoffer Johansen
Elisabeth Anne Wreford Andersen
Pernille Tine Jensen
Ligita Paskeviciute Frøding
Henrik Lajer
Susanne K. Kjaer
Publication date
01-12-2020
Publisher
Springer US
Published in
Journal of Cancer Survivorship / Issue 6/2020
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-020-00899-3

Other articles of this Issue 6/2020

Journal of Cancer Survivorship 6/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine